Your browser is no longer supported. Please, upgrade your browser.
Settings
MNKD MannKind Corporation daily Stock Chart
MNKD [NASD]
MannKind Corporation
Index- P/E- EPS (ttm)-0.52 Insider Own0.20% Shs Outstand488.21M Perf Week1.04%
Market Cap256.80M Forward P/E- EPS next Y-0.18 Insider Trans7.85% Shs Float323.01M Perf Month-19.08%
Income-205.30M PEG- EPS next Q-0.04 Inst Own19.40% Short Float30.96% Perf Quarter-15.84%
Sales162.40M P/S1.58 EPS this Y-76.20% Inst Trans-4.73% Short Ratio20.08 Perf Half Y-46.77%
Book/sh-0.50 P/B- EPS next Y-250.00% ROA-180.40% Target Price- Perf Year-46.59%
Cash/sh0.07 P/C7.23 EPS next 5Y26.80% ROE61.80% 52W Range0.41 - 2.24 Perf YTD-17.39%
Dividend- P/FCF- EPS past 5Y9.60% ROI- 52W High-76.52% Beta3.27
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin58.50% 52W Low28.29% ATR0.04
Employees192 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)35.34 Volatility6.45% 7.21%
OptionableYes Debt/Eq- EPS Q/Q433.40% Profit Margin- Rel Volume0.51 Prev Close0.54
ShortableYes LT Debt/Eq- EarningsFeb 08 AMC Payout- Avg Volume4.98M Price0.53
Recom4.00 SMA20-12.49% SMA50-17.47% SMA200-32.66% Volume2,540,201 Change-1.96%
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Aug-12-14Reiterated RBC Capital Mkts Outperform $16 → $13
Jul-01-14Downgrade MLV & Co Buy → Hold $11
Jun-30-14Reiterated Brinson Patrick Market Outperform $12 → $15
Jun-13-14Initiated RBC Capital Mkts Outperform $16
Apr-02-14Reiterated MLV & Co Buy $9 → $11
Jun-27-13Reiterated MLV & Co Buy $6 → $8
May-15-13Initiated MLV & Co Buy $6
Apr-13-12Initiated Cowen & Co Neutral
Feb-23-12Reiterated JMP Securities Mkt Outperform $7 → $5
Aug-12-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $7
Feb-10-17 09:55AM  Major Biotechs Scare Off Loads of Short Sellers
06:35AM  The 6 Most Shorted Nasdaq Stocks
Feb-07-17 10:16AM  Here's Why MannKind Corporation Rose 11.5% in January at Motley Fool -5.14%
Feb-03-17 08:46AM  Good News and Bad News for MannKind Corporation at Motley Fool
Feb-02-17 02:59PM  MannKind Looks to Boost Flagging Afrezza Sales at Investopedia -17.14%
01:30PM  Here's Why MannKind Corporation Is Plunging at Motley Fool
01:08PM  Mannkind in Free Fall After Changes to Insulin Product, Sales Force
Feb-01-17 09:30AM  Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on MannKind and Keryx Accesswire
09:00AM  MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza® Growth GlobeNewswire
Jan-27-17 09:00AM  MannKind Corporation to Hold Investor Conference Call on February 1, 2017 GlobeNewswire
Jan-26-17 10:35AM  Short Sellers Back Off Major Biotechs
06:25AM  The 6 Most Shorted Nasdaq Stocks
Jan-23-17 09:01AM  Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open +8.13%
Jan-18-17 03:56PM  MannKind Has a New Plan, but Will It Work? at Motley Fool
Jan-12-17 04:00PM  Insulin Drug Offers Hope for MannKind
09:35AM  Biotech Short Sellers Run for Cover
08:02AM  MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
06:35AM  The 6 Most Shorted Nasdaq Stocks
Jan-10-17 04:50PM  MANNKIND CORP Files SEC form 8-K, Other Events
Jan-09-17 12:08PM  Is MannKind Corp. Ready to Rebound in 2017? at Motley Fool -5.57%
09:00AM  MannKind Receives $30.6 Million From Sanofi GlobeNewswire
Jan-05-17 10:27AM  CORRECTING AND REPLACING -- MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference GlobeNewswire
09:00AM  MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference GlobeNewswire
Jan-04-17 09:00AM  MannKind Announces Key Addition to Its Executive Management Ranks GlobeNewswire +7.41%
Jan-03-17 09:00AM  MannKind Receives $1 Million Milestone From RLS GlobeNewswire
Dec-29-16 10:08AM  Galena Biopharma Reveals Regulatory Pathway for GALE-401
09:30AM  Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger
04:44AM  MannKind (MNKD) Shares March Higher, Can It Continue?
Dec-28-16 10:10AM  Biotech Short Interest Sinks
06:25AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Dec-27-16 01:42PM  Nate Pile's Top Recommendations For 2017 at Forbes
Dec-22-16 02:54PM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point at TheStreet
08:03AM  Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
Dec-21-16 08:42AM  Celgene (CELG) Otezla Approved in Japan for Two Indications -9.37%
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 08:42AM  Why MannKind (MNKD) Might Be a Diamond in the Rough +27.66%
Dec-18-16 07:35AM  Tax-Loss Selling: 3 Stocks to Dump Right Now at Motley Fool
Dec-15-16 10:06AM  Is MannKind Corporation (MNKD) a Good Stock to Buy? at Insider Monkey
06:27AM  athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
Dec-14-16 09:17AM  Envision Healthcare Acquires Desert Mountain Consultants
07:39AM  Proteon Slips to 52-Week Low on Kidney Disease Study Data
Dec-13-16 01:11PM  ETFs with exposure to MannKind Corp. : December 13, 2016
09:30AM  Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger
Dec-12-16 09:10AM  Biotech Short Interest Remains Mixed -5.26%
08:35AM  Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
06:35AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Dec-09-16 09:51AM  Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
Dec-07-16 08:55AM  Theravance Stock Up on Fast Track Status for Velusetrag
08:18AM  Better Buy: MannKind Corp. vs. Novo Nordisk at Motley Fool
08:01AM  MANNKIND CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
Dec-06-16 10:07AM  Biotech's Dumbest CEO Moves in 2016 at Motley Fool +10.42%
Dec-01-16 11:24AM  MannKind (MNKD): Strong Industry, Solid Earnings Estimate Revisions
Nov-28-16 09:47AM  3 Biotech Investing Tips That Could Earn You Thousands at Motley Fool
07:35AM  Short Sellers Grow More Aggressive on Major Biotechs
06:55AM  10 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Nov-20-16 07:26AM  Penny Stocks: 2 to Buy, 2 to Avoid at Motley Fool
Nov-17-16 01:04PM  MANNKIND CORP Financials
Nov-14-16 08:35AM  A Trump Victory Sparks Stock Market Surge
08:05AM  MANNKIND CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Nov-11-16 01:26PM  These 5 Stocks Under $10 Could Make You a Lot of Money +6.45%
12:56PM  Sanofi Gets Hosed on MannKind Deal (SNY, MNKD) at Investopedia
11:32AM  Edited Transcript of MNKD earnings conference call or presentation 9-Nov-16 10:00pm GMT
Nov-10-16 03:32PM  Mannkind (MNKD) Q3 Earnings Beat, Inks Deal with Sanofi +33.16%
12:58PM  MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing
11:55AM  Why MannKind Corp. Stock Skyrocketed Today at Motley Fool
07:20AM  Short Sellers Grow More Selective on Major Biotechs
06:35AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Nov-09-16 07:40PM  MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind +8.84%
07:38PM  MannKind and Sanofi Reach Agreement on AFREZZA® GlobeNewswire
06:05PM  Election Results Weren't the Only Reason These Biopharma Stocks Gained up to 33% at Motley Fool
05:10PM  MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Ag
01:22PM  The Only Number in MannKind Corporation's Q3 Results That Really Matters at Motley Fool
09:00AM  MANNKIND CORP Files SEC form 10-Q, Quarterly Report
08:48AM  MannKind posts 3Q profit
08:30AM  MannKind Corporation Reports 2016 Third Quarter Financial Results GlobeNewswire
07:07AM  Q3 2016 MannKind Corp Earnings Release - After Market Close
Nov-01-16 01:13PM  4 Stocks I'd Avoid at All Costs at Motley Fool +6.16%
09:00AM  MannKind Corporation to Hold 2016 Third Quarter Financial Results Conference Call on November 9, 2016 GlobeNewswire
Oct-29-16 08:16AM  3 Stocks to Avoid in Biotech at Motley Fool
Oct-26-16 11:15AM  Is This MannKind's Last Remaining Option? at Motley Fool
07:15AM  Short Sellers Cant Make Up Their Minds on Major Biotechs at 24/7 Wall St.
06:20AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Oct-14-16 06:37PM  MannKind Corporation (MNKD) Stock: One Thing The Company Could Do To Return Value at Insider Monkey -10.06%
Oct-12-16 07:10AM  Short Sellers Have Mixed Views on Major Biotechs at 24/7 Wall St.
06:45AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Oct-11-16 08:21AM  Why MannKind Corp. Stock Fell 15.7% in September at Motley Fool -5.99%
Oct-06-16 08:43PM  These 2 Biotechs Could Vanish by 2018 at Motley Fool
Sep-27-16 07:50AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St. +7.81%
07:15AM  The 6 Most Shorted Nasdaq Stocks at 24/7 Wall St.
Sep-26-16 04:23PM  Can MannKind Compete Against Mylan's EpiPen? (MNKD) at Investopedia -7.13%
Sep-24-16 09:09AM  Biotech Stocks Under $5: 2 to Buy, 1 to Avoid at Motley Fool
Sep-22-16 08:02AM  MANNKIND CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra
Sep-16-16 10:00AM  MNKD: How MannKind's Stock Price Fell 28% in 6 Months at Investopedia
Sep-14-16 01:46PM  MannKind Corp. :MNKD-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016
Sep-13-16 10:00AM  MannKind Stock: 3 Things to Watch (MNKD) at Investopedia
07:05AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
06:10AM  The 6 Most Shorted Nasdaq Stocks: Short Sellers Get Choosy at 24/7 Wall St.
Sep-11-16 09:08AM  3 Stocks to Avoid in the Biotechnology Sector at Motley Fool
Sep-09-16 11:03AM  Why MannKind Corp. Stock Fell 19.1% in August at Motley Fool
Sep-06-16 09:05AM  Valencia company developing inhaler alternative to EpiPen at bizjournals.com
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFEFFER MATTHEW JCEO, CFO, DirectorJan 03Buy0.544,5402,452403,085Jan 04 01:21 PM
Alinaya Rosabel RealicaSVP, Prin Acctg OfficerJan 03Buy0.549,0434,883140,456Jan 04 01:20 PM
Castagna MichaelChief Commercial OfficerAug 26Buy0.7817,50013,650212,500Aug 29 08:53 AM
Castagna MichaelChief Commercial OfficerAug 24Buy0.8715,00013,050195,000Aug 24 06:43 PM
Castagna MichaelChief Commercial OfficerAug 23Buy0.9425,00023,468180,000Aug 24 08:41 AM
PFEFFER MATTHEW JCEO, CFO, DirectorAug 15Buy0.9925,00024,650397,996Aug 16 07:54 AM
Castagna MichaelChief Commercial OfficerAug 12Buy1.0025,00024,88875,000Aug 16 07:56 AM
Alinaya Rosabel RealicaSVP, Prin Acctg OfficerJul 06Sale1.066,2946,672131,413Jul 18 06:30 PM
Castagna MichaelChief Commercial OfficerMay 17Buy0.9350,00046,50050,000May 18 08:00 AM